Marinus Pharmaceuticals Inc

+0.16 (+3.26%)
Earnings Announcements

Marinus Pharmaceuticals Reports Fourth Quarter Results

Published: 03/21/2022 11:23 GMT
Marinus Pharmaceuticals Inc (MRNS) - Resupply of Clinical Trial Materials Has Been Moved Up to May 2022 for Phase 3 Raise Trial.
For Fiscal Year 2022, Company Expects Barda Revenues in Range of $7 Million to $10 Million.
Qtrly Net Loss per Share of Common Stock, Basic and Diluted $0.77.
Q4 Earnings per Share View $-0.76 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.31 Million
Adjusted EPS is expected to be -$0.91

Next Quarter Revenue Guidance is expected to be $3.41 Million
Next Quarter EPS Guidance is expected to be -$0.97

More details on our Analysts Page.